Heterogeneity of tumor endothelial cells

Cancer Science

Volumn 104, Issue 11, 2013, Pages 1391-1395

  Hida, Kyoko ^a   Ohga, Noritaka ^a   Akiyama, Kosuke ^a   Maishi, Nako ^a   Hida, Yasuhiro ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CHEMOKINE; GELATINASE A; GELATINASE B; GROWTH FACTOR; MICRORNA; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR MARKER; VASCULOTROPIN;

ANTIANGIOGENIC THERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL MIGRATION; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; CYTOGENETICS; ENDOTHELIUM CELL; HOST CELL; HUMAN; HYDROSTATIC PRESSURE; HYPOXIA; METASTASIS; METASTATIC MELANOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR CELL; TUMOR ENDOTHELIAL CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL SHAPE; DRUG RESISTANCE, NEOPLASM; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE;

EID: 84886773703     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12251     Document Type: Review

References (47)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86.
2. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-91.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
4. Fidler IJ. Regulation of neoplastic angiogenesis. J Natl Cancer Inst Monogr 2001; 28: 10-4.
5. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res 2002; 62: 5381-5.
6. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9: 713-25.
7. Akino T, Hida K, Hida Y et al. Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 2009; 175: 2657-67.
8. Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006; 66: 2173-80.
9. Hida K, Hida Y, Amin DN et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64: 8249-55.
10. Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008; 99: 459-66.
11. Kurosu T, Ohga N, Hida Y et al. HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer 2011; 104: 819-29.
12. Matsuda K, Ohga N, Hida Y et al. Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 2010; 394: 947-54.
13. Ohga N, Hida K, Hida Y et al. Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated endothelial cells and endothelial progenitor cells. Cancer Sci 2009; 100: 1963-70.
14. Tsuchiya K, Hida K, Hida Y et al. Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol 2010; 36: 1379-86.
15. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-65.
16. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102-11.
17. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000; 97: 14608-13.
18. di Tomaso E, Capen D, Haskell A et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. Cancer Res 2005; 65: 5740-9.
19. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992; 52: 5110-4.
20. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10.
21. Goh PP, Sze DM, Roufogalis BD. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 2007; 7: 743-58.
22. St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-202.
23. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539-54.
24. Hida K, Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 2005; 65: 2507-10.
25. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003; 17: 1159-61.
26. Xiong YQ, Sun HC, Zhang W et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009; 15: 4838-46.
27. Ohga N, Ishikawa S, Maishi N et al. Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am J Pathol 2012; 180: 1294-307.
28. Akiyama K, Ohga N, Hida Y et al. Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol 2012; 180: 1283-93.
29. Mundhekar AN, Bullard DC, Kucik DF. Intracellular heterogeneity in adhesiveness of endothelium affects early steps in leukocyte adhesion. Am J Physiol Cell Physiol 2006; 291: C130-7.
30. Molema G. Heterogeneity in endothelial responsiveness to cytokines, molecular causes, and pharmacological consequences. Semin Thromb Hemost 2010; 36: 246-64.
31. Naito H, Kidoya H, Sakimoto S, Wakabayashi T, Takakura N. Identification and characterization of a resident vascular stem/progenitor cell population in preexisting blood vessels. EMBO J 2011; 31: 842-55.
32. Saubamea B, Cochois-Guegan V, Cisternino S, Scherrmann JM. Heterogeneity in the rat brain vasculature revealed by quantitative confocal analysis of endothelial barrier antigen and P-glycoprotein expression. J Cereb Blood Flow Metab 2012; 32: 81-92.
33. Dudley AC, Khan ZA, Shih SC et al. Calcification of multipotent prostate tumor endothelium. Cancer Cell 2008; 14: 201-11.
34. Langenkamp E, Molema G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Cell Tissue Res 2009; 335: 205-22.
35. Nagy JA, Dvorak HF. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis 2012; 29: 657-62.
36. Bussolati B, Assenzio B, Deregibus MC, Camussi G. The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med (Berl) 2006; 84: 852-63.
37. Takakura N. Role of hematopoietic lineage cells as accessory components in blood vessel formation. Cancer Sci 2006; 97: 568-74.
38. Duensing S, Munger K. Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability. Oncogene 2002; 21: 6241-8.
39. Sato Y. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy. Cancer Sci 2011; 102: 1253-6.
40. Helfrich I, Scheffrahn I, Bartling S et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010; 207: 491-503.
41. Taylor SM, Nevis KR, Park HL et al. Angiogenic factor signaling regulates centrosome duplication in endothelial cells of developing blood vessels. Blood 2010; 116: 3108-17.
42. Gao D, Nolan D, McDonnell K et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009; 1796: 33-40.
43. Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-8.
44. Wang R, Chadalavada K, Wilshire J et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-33.
45. Cheng L, Huang Z, Zhou W et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013; 153: 139-52.
46. Streubel B, Chott A, Huber D et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 250-9.
47. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.